Serotonin and its role in colonic function and in gastrointestinal disorders

Diseases of the Colon and Rectum

Volumn 50, Issue 3, 2007, Pages 376-388

  Costedio, Meagan M ^a   Hyman, Neil ^a   Mawe, Gary M ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

5 HT 3 and 5 HT4 receptors; Constipation; Enterochromaffin cells; Irritable bowel syndrome

Indexed keywords

4,7 DIHYDRO 7 OXO N (3 QUINUCLIDINYL)THIENO[3,2 B]PYRIDINE 6 CARBOXAMIDE; ALOSETRON; CHOLINESTERASE INHIBITOR; CILANSETRON; CISAPRIDE; DOLASETRON MESILATE; GRANISETRON; MOSAPRIDE CITRATE; NEOSTIGMINE; ONDANSETRON; PALONOSETRON; PIBOSEROD; PROKINETIC AGENT; PRUCALOPRIDE; RAMOSETRON; RENZAPRIDE; SEROTONIN; SEROTONIN 3 AGONIST; SEROTONIN 3 ANTAGONIST; SEROTONIN 3 RECEPTOR; SEROTONIN 4 AGONIST; SEROTONIN 4 ANTAGONIST; SEROTONIN 4 RECEPTOR; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; TEGASEROD; UNCLASSIFIED DRUG;

CENTRAL NERVOUS SYSTEM; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLON; COLON DISEASE; COLON MOTILITY; COLON RESECTION; CONSTIPATION; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG TARGETING; ENTERITIS; ENTEROCHROMAFFIN CELL; FUNCTIONAL DISEASE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL INFECTION; HUMAN; IDIOPATHIC DISEASE; INFECTION COMPLICATION; INTESTINE FUNCTION; INTESTINE INNERVATION; INTESTINE MOTILITY; INTESTINE MUCOSA; INTESTINE SECRETION; IRRITABLE COLON; ISCHEMIC COLITIS; NAUSEA; NONHUMAN; OGILVIE SYNDROME; PATHOPHYSIOLOGY; REVIEW; SENSATION; SEROTONIN METABOLISM; SEROTONIN RELEASE; SIGNAL TRANSDUCTION; STOMACH EMPTYING; ULCERATIVE COLITIS;

ANIMALS; COLON; GASTROINTESTINAL DISEASES; GASTROINTESTINAL TRACT; HUMANS; RECEPTORS, SEROTONIN; SEROTONIN; SEROTONIN AGENTS; SEROTONIN ANTAGONISTS; SIGNAL TRANSDUCTION;

EID: 33947174847     PISSN: 00123706     EISSN: 15300358     Source Type: Journal    
DOI: 10.1007/s10350-006-0763-3     Document Type: Review

References (132)

1. WM Bayliss EH Starling 1899 The movements and innervation of the small intestine J Physiol 24 99 143
2. WM Bayliss EH Starling 1900 The movements and innervation of the small intestine J Physiol 26 107 138
3. E Bulbring A Crema 1959 The release of 5-hydroxytryptamine in relation to pressure exerted on the intestinal mucosa J Physiol 146 18 28
4. V Erspamer M Vialli 1937 Ricerche sul secreto delle cellule enterochromaffini Boll Soc Med Chir Pavia 51 357 363
5. PM Whitaker-Azmitia 1999 The discovery of serotonin and its role in neuroscience Neuropsychopharmacology 21 2S 8S
6. IH Page 1952 The vascular action of natural serotonin, 5- and 7-hydroxytryptamine and tryptamine J Pharmacol Exp Ther 105 58 73
7. IH Page 1954 Serotonin (5-hydroxytryptamine) Physiol Rev 34 563 588
8. E Bulbring A Crema 1959 The action of 5-hydroxytryptamine, 5-hydroxytryptophan and reserpine on intestinal peristalsis in anaesthetized guinea-pigs J Physiol 146 29 53
9. E Bulbring RC Lin 1958 The effect of intraluminal application of 5-hydroxytryptamine and 5-hydroxytryptophan on peristalsis; the local production of 5-HT and its release in relation to intraluminal pressure and propulsive activity J Physiol 140 381 407
10. K Racke A Reimann H Schworer H Kilbinger 1996 Regulation of 5-HT release from enterochromaffin cells Behav Brain Res 73 83 87
11. K Racke H Schworer 1991 Regulation of serotonin release from the intestinal mucosa Pharmacol Res 23 13 25
12. JH Gaddum ZP Picarelli 1957 Two kinds of tryptamine receptor Br J Pharmacol Chemother 12 323 328
13. MD Gershon 1968 Serotonin and the motility of the gastrointestinal tract Gastroenterology 54 453 456
14. DY Kim M Camilleri 2000 Serotonin: A mediator of the brain-gut connection Am J Gastroenterol 95 2698 2709
15. RR Gershon D Vlahov G Kelen B Conrad L Murphy 1995 Review of accidents/injuries among emergency medical services workers in Baltimore, Maryland Prehospital Disaster Med 10 14 18
16. MD Gershon 2004 Review article: Serotonin receptors and transporters-roles in normal and abnormal gastrointestinal motility Aliment Pharmacol Ther 20 Suppl 7 3 14
17. MD Crowell MA Shetzline PL Moses GM Mawe NJ Talley 2004 Enterochromaffin cells and 5-HT signaling in the pathophysiology of disorders of gastrointestinal function Curr Opin Investig Drugs 5 55 60
18. RK Goyal I Hirano 1996 The enteric nervous system N Engl J Med 334 1106 1115
19. E Bulbring MD Gershon 1967 5-hydroxytryptamine participation in the vagal inhibitory innervation of the stomach J Physiol 192 823 846
20. D Grundy 2002 Towards a reduction of rectal pain? Neurogastroenterol Motil 14 217 219
21. AJ Kirkup AM Brunsden D Grundy 2001 Receptors and transmission in the brain-gut axis: Potential for novel therapies. I. Receptors on visceral afferents Am J Physiol Gastrointest Liver Physiol 280 G787 G794
22. RW Fuller DT Wong 1990 Serotonin uptake and serotonin uptake inhibition Ann N Y Acad Sci 600 68 80
23. M Da Prada JP Tranzer A Pletscher 1972 Storage of 5-hydroxytryptamine in human blood platelets Experientia 28 1328 1329
24. MD Gershon 1991 Serotonin: Its role and receptors in enteric neurotransmission Adv Exp Med Biol 294 221 230
25. DI Wallis CE Stansfeld HL Nash 1982 Depolarizing responses recorded from nodose ganglion cells of the rabbit evoked by 5-hydroxytryptamine and other substances Neuropharmacology 21 31 40
26. BD Cash WD Chey 2005 Review article: The role of serotonergic agents in the treatment of patients with primary chronic constipation Aliment Pharmacol Ther 22 1047 1060
27. AC Hargreaves SC Lummis CW Taylor 1994 Ca2+ permeability of cloned and native 5-hydroxytryptamine type 3 receptors Mol Pharmacol 46 1120 1128
28. M Camilleri 2004 Treating irritable bowel syndrome: Overview, perspective and future therapies Br J Pharmacol 141 1237 1248
29. F Cremonini S Delgado-Aros M Camilleri 2003 Efficacy of alosetron in irritable bowel syndrome: A meta-analysis of randomized controlled trials Neurogastroenterol Motil 15 79 86
30. M Delvaux D Louvel JP Mamet R Campos-Oriola J Frexinos 1998 Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome Aliment Pharmacol Ther 12 849 855
31. RH Jones G Holtmann L Rodrigo 1999 Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients Aliment Pharmacol Ther 13 1419 1427
32. T Lembo RA Wright B Bagby 2001 Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome Am J Gastroenterol 96 2662 2670
33. KW Olden MD Crowell 2005 Cilansetron Drugs Today (Barc) 41 661 666
34. LJ Brandt CM Prather EM Quigley LR Schiller P Schoenfeld NJ Talley 2005 Systematic review on the management of chronic constipation in north america Am J Gastroenterol 100 Suppl 1 S5 S21
35. MJ Callahan 2002 Irritable bowel syndrome neuropharmacology. A review of approved and investigational compounds J Clin Gastroenterol 35 S58 S67
36. M Camilleri 2001 Review article: Tegaserod Aliment Pharmacol Ther 15 277 289
37. Evans BW, Clark WK, Moore DJ, Whorwell PJ. Tegaserod for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2004; CD003960
38. MA Kamm S Muller-Lissner NJ Talley 2005 Tegaserod for the treatment of chronic constipation: A randomized, double-blind, placebo-controlled multinational study Am J Gastroenterol 100 362 372
39. SA Muller-Lissner I Fumagalli KD Bardhan 2001 Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation Aliment Pharmacol Ther 15 1655 1666
40. H Nyhlin C Bang L Elsborg 2004 A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome Scand J Gastroenterol 39 119 126
41. J Jailwala TF Imperiale K Kroenke 2000 Pharmacologic treatment of the irritable bowel syndrome: A systematic review of randomized, controlled trials Ann Intern Med 133 136 147
42. MA Kamm 2002 Review article: The complexity of drug development for irritable bowel syndrome Aliment Pharmacol Ther 16 343 351
43. DJ Ziegenhagen W Kruis 2004 Cisapride treatment of constipation- predominant irritable bowel syndrome is not superior to placebo J Gastroenterol Hepatol 19 744 749
44. EP Bouras M Camilleri DD Burton G Thomforde S [tmp] McKinzie AR Zinsmeister 2001 Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder Gastroenterology 120 354 360
45. G Coremans R Kerstens M De Pauw M Stevens 2003 Prucalopride is effective in patients with severe chronic constipation in whom laxatives fail to provide adequate relief. Results of a double-blind, placebo-controlled clinical trial Digestion 67 82 89
46. AM De Schryver GI Andriesse M Samsom AJ Smout HG Gooszen LM Akkermans 2002 The effects of the specific 5HT(4) receptor agonist, prucalopride, on colonic motility in healthy volunteers Aliment Pharmacol Ther 16 603 612
47. AV Emmanuel AJ Roy TJ Nicholls MA Kamm 2002 Prucalopride, a systemic enterokinetic, for the treatment of constipation Aliment Pharmacol Ther 16 1347 1356
48. CE Sloots AC Poen R Kerstens 2002 Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation Aliment Pharmacol Ther 16 759 767
49. AE Bharucha M Camilleri S Haydock 2000 Effects of a serotonin 5-HT(4) receptor antagonist sb-207266 on gastrointestinal motor and sensory function in humans Gut 47 667 674
50. LA Houghton NA Jackson PJ Whorwell SM Cooper 1999 5-HT4 receptor antagonism in irritable bowel syndrome: Effect of sb-207266-a on rectal sensitivity and small bowel transit Aliment Pharmacol Ther 13 1437 1444
51. GJ Sanger SE Banner MI Smith KA Wardle 1998 Sb-207266: 5-HT4 receptor antagonism in human isolated gut and prevention of 5-HT-evoked sensitization of peristalsis and increased defaecation in animal models Neurogastroenterol Motil 10 271 279
52. M Tonini F De Ponti A Di Nucci F Crema 1999 Review article: Cardiac adverse effects of gastrointestinal prokinetics Aliment Pharmacol Ther 13 1585 1591
53. M Camilleri S [tmp] McKinzie J Fox 2004 Effect of renzapride on transit in constipation-predominant irritable bowel syndrome Clin Gastroenterol Hepatol 2 895 904
54. JJ Galligan S Vanner 2005 Basic and clinical pharmacology of new motility promoting agents Neurogastroenterol Motil 17 643 653
55. F Potet T Bouyssou D Escande I Baro 2001 Gastrointestinal prokinetic drugs have different affinity for the human cardiac human ether-a-gogo k(+) channel J Pharmacol Exp Ther 299 1007 1012
56. L Carlsson GJ Amos B Andersson L Drews G Duker G Wadstedt 1997 Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: Implications for proarrhythmic potential? J Pharmacol Exp Ther 282 220 227
57. Y Mine T Yoshikawa S Oku R Nagai N Yoshida K Hosoki 1997 Comparison of effect of mosapride citrate and existing 5-HT4 receptor agonists on gastrointestinal motility in vivo and in vitro J Pharmacol Exp Ther 283 1000 1008
58. PP Bertrand WA Kunze JB Furness JC Bornstein 2000 The terminals of myenteric intrinsic primary afferent neurons of the guinea-pig ileum are excited by 5-hydroxytryptamine acting at 5-hydroxytryptamine-3 receptors Neuroscience 101 459 469
59. JJ Galligan 1996 Electrophysiological studies of 5-hydroxytryptamine receptors on enteric neurons Behav Brain Res 73 199 201
60. JJ Galligan 2002 Pharmacology of synaptic transmission in the enteric nervous system Curr Opin Pharmacol 2 623 629
61. B Costall RJ Naylor 2004 5-HT3 receptors Curr Drug Targets CNS Neurol Disord 3 27 37
62. NJ Talley SF Phillips A Haddad 1990 Gr 38032f (ondansetron), a selective 5HT3 receptor antagonist, slows colonic transit in healthy man Dig Dis Sci 35 477 480
63. MR von der Ohe RB Hanson M Camilleri 1994 Serotonergic mediation of postprandial colonic tonic and phasic responses in humans Gut 35 536 541
64. M Camilleri WY Chey EA Mayer 2001 A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome Arch Intern Med 161 1733 1740
65. M Camilleri AR Northcutt S Kong GE Dukes D [tmp] McSorley AW Mangel 2000 Efficacy and safety of alosetron in women with irritable bowel syndrome: A randomised, placebo-controlled trial Lancet 355 1035 1040
66. J Bockaert S Claeysen V Compan A Dumuis 2004 5-HT4 receptors Curr Drug Targets CNS Neurol Disord 3 39 51
67. AE Foxx-Orenstein JG Jin JR Grider 1998 5-HT4 receptor agonists and delta-opioid receptor antagonists act synergistically to stimulate colonic propulsion Am J Physiol 275 G979 G983
68. M Liu MS Geddis Y Wen W Setlik MD Gershon 2005 Expression and function of 5-HT4 receptors in the mouse enteric nervous system Am J Physiol Gastrointest Liver Physiol 289 G1148 G1163
69. JR Grider 2006 Desensitization of the peristaltic reflex induced by mucosal stimulation with the selective 5-HT4 agonist tegaserod Am J Physiol Gastrointest Liver Physiol 290 G319 G327
70. JJ Galligan H Pan E Messori 2003 Signalling mechanism coupled to 5-hydroxytryptamine4 receptor-mediated facilitation of fast synaptic transmission in the guinea-pig ileum myenteric plexus Neurogastroenterol Motil 15 523 529
71. H Pan JJ Galligan 1994 5-HT1a and 5-HT4 receptors mediate inhibition and facilitation of fast synaptic transmission in enteric neurons Am J Physiol 266 G230 G238
72. JR Grider AE Foxx-Orenstein JG Jin 1998 5-Hydroxytryptamine4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine Gastroenterology 115 370 380
73. JG Jin AE Foxx-Orenstein JR Grider 1999 Propulsion in guinea pig colon induced by 5-hydroxytryptamine (HT) via 5-HT4 and 5-HT3 receptors J Pharmacol Exp Ther 288 93 97
74. G Lyford A Foxx-Orenstein 2004 Chronic intestinal pseudoobstruction Curr Treat Options Gastroenterol 7 317 325
75. A Ferriman 2000 UK licence for cisapride suspended BMJ 321 259
76. DR Linden JX Chen MD Gershon KA Sharkey GM Mawe 2003 Serotonin availability is increased in mucosa of guinea pigs with tnbs-induced colitis Am J Physiol Gastrointest Liver Physiol 285 G207 G216
77. JR O'Hara W Ho DR Linden GM Mawe KA Sharkey 2004 Enteroendocrine cells and 5-HT availability are altered in mucosa of guinea pigs with TNBS ileitis Am J Physiol Gastrointest Liver Physiol 287 G998 G1007
78. DR Linden KF Foley C [tmp] McQuoid J Simpson KA Sharkey GM Mawe 2005 Serotonin transporter function and expression are reduced in mice with TNBS-induced colitis Neurogastroenterol Motil 17 565 74
79. J Wheatcroft D Wakelin A Smith CR Mahoney G Mawe R Spiller 2005 Enterochromaffin cell hyperplasia and decreased serotonin transporter in a mouse model of postinfectious bowel dysfunction Neurogastroenterol Motil 17 863 870
80. JR O'Hara AC Skinn WK [tmp] MacNaughton PM Sherman KA Sharkey 2006 Consequences of Citrobacter rodentium infection on enteroendocrine cells and the enteric nervous system in the mouse colon Cell Microbiol 8 646 660
81. MD Coates CR Mahoney DR Linden 2004 Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome Gastroenterology 126 1657 1664
82. A Ahonen K Kyosola O Penttila 1976 Enterochromaffin cells in macrophages in ulcerative colitis and irritable colon Ann Clin Res 8 1 7
83. F Magro MA Vieira-Coelho S Fraga 2002 Impaired synthesis or cellular storage of norepinephrine, dopamine, and 5-hydroxytryptamine in human inflammatory bowel disease Dig Dis Sci 47 216 224
84. M El-Salhy A Danielsson R Stenling L Grimelius 1997 Colonic endocrine cells in inflammatory bowel disease J Intern Med 242 413 419
85. CP Bearcroft D Perrett MJ Farthing 1998 Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: A pilot study Gut 42 42 46
86. J Miwa H Echizen K Matsueda N Umeda 2001 Patients with constipation-predominant irritable bowel syndrome (IBS) may have elevated serotonin concentrations in colonic mucosa as compared with diarrhea-predominant patients and subjects with normal bowel habits Digestion 63 188 194
87. W Atkinson S Lockhart PJ Whorwell B Keevil LA Houghton 2006 Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome Gastroenterology 130 34 43
88. SP Dunlop NS Coleman E Blackshaw 2005 Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome Clin Gastroenterol Hepatol 3 349 357
89. RC Spiller D Jenkins JP Thornley 2000 Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome Gut 47 804 811
90. SP Dunlop D Jenkins KR Neal RC Spiller 2003 Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS Gastroenterology 125 1651 1659
91. J Lincoln R Crowe MA Kamm G Burnstock JE Lennard-Jones 1990 Serotonin and 5-hydroxyindoleacetic acid are increased in the sigmoid colon in severe idiopathic constipation Gastroenterology 98 1219 1225
92. R Zhao MK Baig SD Wexner 2000 Enterochromaffin and serotonin cells are abnormal for patients with colonic inertia Dis Colon Rectum 43 858 863
93. M Simren J Axelsson R Gillberg H Abrahamsson J Svedlund ES Bjornsson 2002 Quality of life in inflammatory bowel disease in remission: The impact of IBS-like symptoms and associated psychological factors Am J Gastroenterol 97 389 396
94. KR Neal J Hebden R Spiller 1997 Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: Postal survey of patients BMJ 314 779 782
95. DA Drossman WE Whitehead M Camilleri 1997 Irritable bowel syndrome: A technical review for practice guideline development Gastroenterology 112 2120 2137
96. VS Chadwick W Chen D Shu 2002 Activation of the mucosal immune system in irritable bowel syndrome Gastroenterology 122 1778 1783
97. H Tornblom G Lindberg B Nyberg B Veress 2002 Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome Gastroenterology 123 1972 1979
98. H Mertz V Morgan G Tanner 2000 Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distention Gastroenterology 118 842 848
99. GR Locke 3rd AR Zinsmeister NJ Talley SL Fett LJ Melton 3rd 2000 Familial association in adults with functional gastrointestinal disorders Mayo Clin Proc 75 907 912
100. S Nobaek ML Johansson G Molin S Ahrne B Jeppsson 2000 Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome Am J Gastroenterol 95 1231 1238
101. MD Gershon 2005 Nerves, reflexes, and the enteric nervous system: Pathogenesis of the irritable bowel syndrome J Clin Gastroenterol 39 S184 S193
102. JJ Chen Z Li H Pan 2001 Maintenance of serotonin in the intestinal mucosa and ganglia of mice that lack the high-affinity serotonin transporter: Abnormal intestinal motility and the expression of cation transporters J Neurosci 21 6348 6361
103. MD Coates AC Johnson B Greenwood-Van Meerveld GM Mawe 2006 Effects of serotonin transporter inhibition on gastrointestinal motility and colonic sensitivity in the mouse Neurogastroenterol Motil 18 464 471
104. M Camilleri EA Mayer DA Drossman 1999 Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist Aliment Pharmacol Ther 13 1149 1159
105. F De Ponti M Tonini 2001 Irritable bowel syndrome: New agents targeting serotonin receptor subtypes Drugs 61 317 332
106. CH Knowles M Scott PJ Lunniss 1999 Outcome of colectomy for slow transit constipation Ann Surg 230 627 638
107. A Sonnenberg TR Koch 1989 Epidemiology of constipation in the United States Dis Colon Rectum 32 1 8
108. WA Voderholzer W Schatke BE Muhldorfer AG Klauser B Birkner SA Muller-Lissner 1997 Clinical response to dietary fiber treatment of chronic constipation Am J Gastroenterol 92 95 98
109. CL He L Burgart L Wang 2000 Decreased interstitial cell of Cajal volume in patients with slow-transit constipation Gastroenterology 118 14 21
110. WD Tong BH Liu LY Zhang SB Zhang Y Lei 2004 Decreased interstitial cells of Cajal in the sigmoid colon of patients with slow transit constipation Int J Colorectal Dis 19 467 473
111. P Facer CH Knowles PK Thomas PK Tam NS Williams P Anand 2001 Decreased tyrosine kinase C expression may reflect developmental abnormalities in Hirschsprung's disease and idiopathic slow-transit constipation Br J Surg 88 545 552
112. CH Knowles SA Gayther M Scott 2000 Idiopathic slow-transit constipation is not associated with mutations of the ret proto-oncogene or GDNF Dis Colon Rectum 43 851 857
113. DF Altomare P Portincasa M Rinaldi 1999 Slow-transit constipation: Solitary symptom of a systemic gastrointestinal disease Dis Colon Rectum 42 231 240
114. ZL Xiao V Pricolo P Biancani J Behar 2005 Role of progesterone signaling in the regulation of g-protein levels in female chronic constipation Gastroenterology 128 667 675
115. L Bueno J Fioramonti 1988 Action of opiates on gastrointestinal function Baillieres Clin Gastroenterol 2 123 139
116. KJ Fotherby JO Hunter 1987 Idiopathic slow-transit constipation: Whole gut transit times, measured by a new simplified method, are not shortened by opioid antagonists Aliment Pharmacol Ther 1 331 338
117. E Sonsino R Mouy P Foucaud 1984 Intestinal pseudo-obstruction related to cytomegalovirus infection of myenteric plexus N Engl J Med 311 196 197
118. NP Sykes 1991 Oral naloxone in opioid-associated constipation Lancet 337 1475
119. M Vassallo M Camilleri BL Caron PA Low 1991 Gastrointestinal motor dysfunction in acquired selective cholinergic dysautonomia associated with infectious mononucleosis Gastroenterology 100 252 258
120. CH Knowles JE Martin 2000 Slow transit constipation: A model of human gut dysmotility. Review of possible aetiologies Neurogastroenterol Motil 12 181 196
121. RH Zhao MK Baig KJ Thaler 2003 Reduced expression of serotonin receptor(s) in the left colon of patients with colonic inertia Dis Colon Rectum 46 81 86
122. JF Johanson A Wald G Tougas 2004 Effect of tegaserod in chronic constipation: A randomized, double-blind, controlled trial Clin Gastroenterol Hepatol 2 796 805
123. MF Piccirillo P Reissman SD Wexner 1995 Colectomy as treatment for constipation in selected patients Br J Surg 82 898 901
124. GP FitzHarris J Garcia-Aguilar SC Parker 2003 Quality of life after subtotal colectomy for slow-transit constipation: Both quality and quantity count Dis Colon Rectum 46 433 440
125. MD Saunders MB Kimmey 2005 Systematic review: Acute colonic pseudo-obstruction Aliment Pharmacol Ther 22 917 925
126. R De Giorgio G Barbara V Stanghellini 2001 Review article: The pharmacological treatment of acute colonic pseudo-obstruction Aliment Pharmacol Ther 15 1717 1727
127. H Paran D Silverberg A Mayo I Shwartz D Neufeld U Freund 2000 Treatment of acute colonic pseudo-obstruction with neostigmine J Am Coll Surg 190 315 318
128. RJ Ponec MD Saunders MB Kimmey 1999 Neostigmine for the treatment of acute colonic pseudo-obstruction N Engl J Med 341 137 141
129. BM Stephenson AR Morgan JR Salaman MH Wheeler 1995 Ogilvie's syndrome: A new approach to an old problem Dis Colon Rectum 38 424 427
130. GT Trevisani NH Hyman JM Church 2000 Neostigmine: Safe and effective treatment for acute colonic pseudo-obstruction Dis Colon Rectum 43 599 603
131. C [tmp] MacColl KL [tmp] MacCannell B Baylis SS Lee 1990 Treatment of acute colonic pseudo-obstruction (Ogilvie's syndrome) with cisapride Gastroenterology 98 773 776
132. PA Pelckmans PP Michielsen PG Jorens YM Van Maercke 1990 Cisapride in Ogilvie's syndrome Gastroenterology 99 1194 5